CN111773227A - Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 - Google Patents
Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 Download PDFInfo
- Publication number
- CN111773227A CN111773227A CN202010639186.0A CN202010639186A CN111773227A CN 111773227 A CN111773227 A CN 111773227A CN 202010639186 A CN202010639186 A CN 202010639186A CN 111773227 A CN111773227 A CN 111773227A
- Authority
- CN
- China
- Prior art keywords
- taurolidine
- novel coronavirus
- cov
- application
- coronavirus sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an application of taurolidine in preparing a medicine for resisting novel coronavirus SARS-CoV-2, relating to the technical field of medicines. The invention discovers the new application of the taurolidine for the first time, namely the application of the taurolidine in inhibiting the novel coronavirus SARS-CoV-2 or preparing the medicine for resisting the novel coronavirus SARS-CoV-2. The safety of the taurolidine to human bodies is detected by clinical practice, the invention discovers the obvious drug effect of the taurolidine to the novel coronavirus SARS-CoV-2, provides powerful theoretical basis and practical basis for resisting the novel coronavirus COVID-19, and has development value and popularization significance. The invention provides a new approach for treating the novel coronavirus pneumonia.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of taurolidine in preparing a medicine for resisting novel coronavirus SARS-CoV-2.
Background
The novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) is called new coronavirus pneumonia for short, and the world health organization is named as '2019 coronavirus Disease'. It is a contagious disease mainly characterized by fever, dry cough, hypodynamia and certain lethality rate, which are caused by a novel coronavirus SARS-CoV-2. Until now, no specific medicine for treating the novel coronavirus pneumonia exists.
Chinese patents CN101274921A and CN101285813A disclose that Taurolidine (Taurolidine) has a chemical name: 4,4 ' -methylenebis- (tetrahydro-2H-1, 2, 4-thiadiazine) -1,1,1 ', 1 ' tetraoxide with the molecular formula C7H16N4O4S2The molecular weight is: 284.348, is white or white-like crystalline powder, and has the following chemical formula:
can be synthesized by the following synthetic route:
taurolidine is a broad spectrum antibacterial, antifungal and antiendotoxic drug. Is mainly used for preventing the junior symptoms of patients suffering from various blood stream infections related to the catheter. It can also be used for treating otitis, pleuropneumonia, osteomyelitis, dermatitis, periodontitis, gingivitis, acne, and ulcer. However, no use of taurolidine for the novel coronavirus SARS-CoV-2 has been found so far.
Disclosure of Invention
The invention aims to provide a new application of taurolidine, namely the application of taurolidine in inhibiting novel coronavirus SARS-CoV-2 or preparing medicaments for resisting novel coronavirus SARS-CoV-2.
In the technical scheme, the taurolidine is prepared into injection, infusion solution, tablets, capsules and the like, and the infusion solution is preferred.
The invention has the beneficial effects that:
the invention discovers the new application of the taurolidine for the first time, namely the application of the taurolidine in inhibiting the novel coronavirus SARS-CoV-2 or preparing the medicine for resisting the novel coronavirus SARS-CoV-2. The safety of taurolidine to human body has been tested by clinical practice, the invention discovers the obvious drug effect of taurolidine to novel coronavirus SARS-CoV-2, provides powerful theoretical basis and practical basis for resisting novel coronavirus SARS-CoV-2, and has development value and popularization significance. The invention provides a new approach for treating the novel coronavirus pneumonia.
Detailed Description
In order that the nature of the invention may be better understood, the invention will now be described in further detail with reference to specific examples, which are intended to be illustrative of the invention and not to be limiting of the invention. Next, the inhibitory effect of taurolidine on the novel coronavirus SARS-CoV-2 was examined at the cellular level.
Firstly, experimental materials:
1.1 cells 293T cells from the military veterinary institute virology laboratory;
1.2 strain SARS-CoV-2 virus, from the virology research laboratory of the military veterinary institute;
1.3 reagent DMEM medium, 0.25% trypsin, FBS, PBS (FH ═ 7.0);
1.4 instrument consumable pipettor and supporting suction head, 1.5mL centrifuging tube, ice box, ice machine, biological safety cabinet, carbon dioxide incubator.
II, an experimental method:
2.1 the cell culture recovers 293T cells, continuously transmits the 293T cells for three generations, and is used for experimental study after the cells grow well;
2.2 Virus culture the preserved virus liquid is placed on ice to be slowly melted and then inoculated to a single layer of 293T cells (no more than 24 hours), the culture is continued for 72 to 96 hours, and the virus liquid is harvested according to the cytopathic state. And determining the virus content as TCID50The unit of calculation is/100. mu.L.
2.3 taurolidine inhibition
Drugs are mixed with virus and simultaneously inoculated into cells: the 293T cells with good growth condition are digested by pancreatin, the cell content is calculated, and the cells are inoculated in 96 holesPlate, each hole 105Individual cells, seeded within 12 hours and in monolayer state for study of drug action. Inoculation virus content of 200 TCIDs50The SARS-CoV-2 virus and taurolidine are mixed and immediately inoculated into a paved 96-well plate, and the 2 percent taurolidine solution and the drug dosage are 50 mu L, 25 mu L, 12.5 mu L, 7.5 mu L and 3.75 mu L. Setting blank cell control and taurolidine cytotoxicity control, and repeating for 3 times;
placing the inoculated cell plate at 37 ℃ and CO2In the incubator, the culture was continued and the cytopathic effect was observed.
Third, experimental results
According to the above experimental method, CO is maintained at 37 deg.C2The cell state was observed in the incubator for 72 hours, and the cell state was good and no cytopathic effect was observed under the microscope in the case of 50. mu.L and 25. mu.L of the drug as the inoculum dose. The cytopathic effect of 12.5. mu.L, 7.5. mu.L and 3.75. mu.L appeared to different degrees, and the inoculation dose of 3.75. mu.L was used as the group and 200TCID was used50The cytopathic effect was not different.
Fourthly, judging the result
Based on the above experimental results, it was determined that 200TCID was completely inhibited when the drug was administered in a dose of 50. mu.L or 25. mu.L50200TCID was not completely inhibited by 12.5. mu.L, 7.5. mu.L of the inoculum dose50Virus-infected cells failed to inhibit 200TCID at an inoculum dose of 3.75. mu.L50The virus infects the cells.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (4)
1. Application of taurolidine in inhibiting novel coronavirus SARS-CoV-2 is provided.
2. An application of taurolidine in preparing the medicines for treating the SARS-CoV-2 caused by coronavirus is disclosed.
3. The use of claim 2, wherein the taurolidine is in the form of an injection, infusion, tablet, or capsule.
4. The use of claim 3, wherein said taurolidine is in the form of an infusion solution.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010639186.0A CN111773227A (en) | 2020-07-06 | 2020-07-06 | Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 |
| CN202110752333.XA CN113491700B (en) | 2020-07-06 | 2021-07-02 | Application of taurolidine in antivirus |
| BR112023000308A BR112023000308A2 (en) | 2020-07-06 | 2021-07-02 | USE OF TAUROLIDINE AGAINST VIRUSES |
| PCT/CN2021/104197 WO2022007713A1 (en) | 2020-07-06 | 2021-07-02 | Use of taurolidine against virus |
| JP2023501231A JP2023533041A (en) | 2020-07-06 | 2021-07-02 | Use of Taurolidine against viruses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010639186.0A CN111773227A (en) | 2020-07-06 | 2020-07-06 | Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111773227A true CN111773227A (en) | 2020-10-16 |
Family
ID=72758809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010639186.0A Withdrawn CN111773227A (en) | 2020-07-06 | 2020-07-06 | Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773227A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491700A (en) * | 2020-07-06 | 2021-10-12 | 军事科学院军事医学研究院军事兽医研究所 | Application of taurolidine in antivirus |
| CN114796235A (en) * | 2021-01-28 | 2022-07-29 | 华中科技大学 | Application of taurocholic acid and water-soluble salt thereof in inhibiting activity of endoribonuclease of new coronavirus |
-
2020
- 2020-07-06 CN CN202010639186.0A patent/CN111773227A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491700A (en) * | 2020-07-06 | 2021-10-12 | 军事科学院军事医学研究院军事兽医研究所 | Application of taurolidine in antivirus |
| WO2022007713A1 (en) * | 2020-07-06 | 2022-01-13 | 军事科学院军事医学研究院军事兽医研究所 | Use of taurolidine against virus |
| CN114796235A (en) * | 2021-01-28 | 2022-07-29 | 华中科技大学 | Application of taurocholic acid and water-soluble salt thereof in inhibiting activity of endoribonuclease of new coronavirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111773227A (en) | Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 | |
| CN105622596A (en) | Benzothiazine-4-ketone compound containing alkoxyimino azacyclo-fragments and preparation method of benzothiazine-4-ketone compound | |
| CN105669664A (en) | Benzothiazine-4-ketone compounds containing basic nitrogen heterocyclic fragments and preparing methods of benzothiazine-4-ketone compounds | |
| CN111658652A (en) | Application of taurolidine in preparing anti-coronavirus medicine | |
| CN111544451A (en) | Composition for resisting helicobacter pylori and application thereof | |
| CN106632133B (en) | Thiazole derivative and the preparation method and application thereof | |
| CN114377027A (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating or preventing SARS-CoV-2 | |
| CN110812357B (en) | Application of biapenem in preparation of medicine for preventing and treating bovine enterovirus infection | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN102786536A (en) | Sulbactam amoxicillin amide complex for treatment of acute bacterial infection of pig and synthesis method | |
| CN110694065B (en) | Application of histamine receptor inhibitor and derivatives thereof in preparation of anti-Zika virus drugs | |
| CN111617086A (en) | Application of taurolidine in preparing anti-HPV (human papilloma Virus) medicine | |
| CN108853081B (en) | Application of amentoflavone in preparation of medicine for treating necrotic enteritis of chicken | |
| CN111671758A (en) | Application of taurolidine in preparing anti-HIV (human immunodeficiency virus) medicament | |
| CN114306298B (en) | Application of 2,3, 5-triiodo-benzoyl hydrazine in preparing anti-EV 71 virus medicament | |
| CN114452273B (en) | Application of iodized hydrazide and iodized hydrazide polyacid derivative in preparation of CVB3 virus resistant drugs | |
| CN116098893B (en) | Application of compound Thapsigargin in preparation of medicines for preventing or treating porcine epidemic diarrhea | |
| CN110974822B (en) | Pharmaceutical use of ammonium pyrrolidine dithiocarbamate | |
| CN114848634B (en) | Application of SB415286 and Zika virus inhibitor and drug | |
| CN109646435B (en) | Application of ertapenem sodium in preparation of medicine for preventing and treating infectious bovine rhinotracheitis | |
| CN104523849A (en) | Pharmaceutical composition of eucommia ulmoides iridoids and application thereof | |
| CN103462951A (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN116850194A (en) | Application of compound GSK-J4 in preparation of medicine for treating tuberculosis | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN117205192A (en) | Application of compound IMD-0354 in preparing medicament for treating tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201016 |
|
| WW01 | Invention patent application withdrawn after publication |